1053653-19-2

Basic information

• Product Name: Acetic acid 3-[(1S,2S)-1-benzyl-3-((R)-4-tert-butylcarbamoyl-thiazolidin-3-yl)-2-hydroxy-3-oxo-propylcarbamoyl]-phenyl ester
• CAS NO: 1053653-19-2
• Molecular Weight: 527.642
• Mol File: 1053653-19-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Acetic acid 3-[(1S,2S)-1-benzyl-3-((R)-4-tert-butylcarbamoyl-thiazolidin-3-yl)-2-hydroxy-3-oxo-propylcarbamoyl]-phenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Acetic acid 3-[(1S,2S)-1-benzyl-3-((R)-4-tert-butylcarbamoyl-thiazolidin-3-yl)-2-hydroxy-3-oxo-propylcarbamoyl]-phenyl ester(1053653-19-2)
• EPA Substance Registry System: Acetic acid 3-[(1S,2S)-1-benzyl-3-((R)-4-tert-butylcarbamoyl-thiazolidin-3-yl)-2-hydroxy-3-oxo-propylcarbamoyl]-phenyl ester(1053653-19-2)

Safety Data

• Hazardous Substances Data: 1053653-19-2(Hazardous Substances Data)

Upstream product

• 147318-83-0 [(1S,2S)-1-Benzyl-3-((R)-4-tert-butylcarbamoyl-thiazolidin-3-yl)-2-hydroxy-3-oxo-propyl]-carbamic acid tert-butyl ester 
• 148982-94-9 N-tert-butyl-3-(tert-butoxycarbonyl)thiazolidine-4-carboxamide 
• 128019-19-2 (R)-N-tert-butyl-1,3-thiazolidine-4-carboxamide 
• 62023-65-8 (2S,3S)-3-tert-butoxycarbonylamino-2-hydroxy-4-phenylbutanoic acid 
• 6304-89-8 3-acetoxybenzoic acid 
• 158941-63-0 (R)-N-tert-butyl-3-<(2S,3S)-3-amino-2-hydroxy-4-phenylbutanoyl>-1,3-thiazolidine-4-carboxamide 

Relevant articles and documents

Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine

We designed and synthesized a new class of peptidomimetic human immunodeficiency virus (HIV) protease inhibitors containing a unique unnatural amino acid, allophenylnorstatine [Apns; (2S,3S)-3-amino-2-hydroxy- 4-phenylbutyric acid], with a hydroxymethylcarbonyl (HMC) isostere as the active moiety. A systematic evaluation of structure - activity relationships for HIV protease inhibition, anti-HIV activities, and pharmacokinetic profiles has led to the delineation of a set of structural characteristics that appear to afford an orally available HIV protease inhibitor. Optimum structures, exemplified by 21f (JE-2147), incorporated 3-hydroxy-2- methylbenzoyl groups as the P2 ligand, (R)-5,5-dimethyl-1,3-thiazolidine-4- carbonyl (Dmt) residue at the P1' site, and 2-methylbenzylcarboxamide group as the P2' ligand. The present study demonstrated that JE-2147 has potent antiviral activities in vitro and exhibits good oral bioavailability and plasma pharmacokinetic profiles in two species of laboratory animals.